Press release
Severe Psoriasis Market Expected to Show Robust Growth Through 2032, Driven by Novel Biologics and Oral Therapeutics | DelveInsight
The severe psoriasis market is experiencing significant expansion with next-generation IL-1 inhibitors, TYK2 blockers, and novel topical formulations addressing the unmet treatment needs. Key psoriasis companies include Johnson & Johnson, Pfizer, LEO Pharma, Novartis, Biocon Biologics, AbbVie, Eli Lilly and Company, Sun Pharmaceutical, Merck, Evelo Biosciences, Inc., Bausch Health Companies Inc., Amgen Inc., Bristol-Myers Squibb Company, Galderma S.A., and InnoCare Pharma, among others.DelveInsight's "Severe Psoriasis - Market Insight, Epidemiology And Market Forecast - 2032 [https://www.delveinsight.com/report-store/severe-psoriasis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report provides comprehensive coverage of the severe psoriasis treatment market, delivering in-depth analysis of historical and forecasted epidemiology alongside market drivers and challenges nacross the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. The report examines current treatment protocols, emerging therapies, market drivers, and barriers while offering detailed severe psoriasis market size forecasts from 2019 through 2032, positioning stakeholders to better understand the evolving treatment paradigm and commercial opportunities in this dynamic therapeutic area.
The severe psoriasis treatment market is rapidly evolving, driven by advancements in biologics, targeted therapies, and innovations in diagnostics and drug delivery. The United States currently captures the largest severe psoriasis market size due to the high prevalence of the disease, advanced healthcare infrastructure, and a strong inclination to adopt new therapies. Plaque psoriasis is the largest segment, representing over half of the overall market, thanks to its high prevalence and the introduction of new combination therapies. Meanwhile, psoriatic arthritis is anticipated to be the fastest-growing segment, reflecting increased awareness and improved diagnostic capabilities.
Download the Severe Psoriasis Market Forecast Report to understand which factors are driving the Severe Psoriasis therapeutic market @ Severe Psoriasis Market Trends [https://www.delveinsight.com/sample-request/severe-psoriasis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Severe psoriasis epidemiological data reveal significant regional variations in the prevalence of moderate-to-severe psoriasis, affecting approximately 0.3% to 1% of the global population. In the US, the burden is notably higher, with nearly 8 million diagnosed psoriasis cases reported in 2023. About 20% to 30% of these cases are classified as moderate or severe. According to the analysis by DelveInsight, the patient population continues to grow across major markets, with demographic patterns showing variable gender distribution in different regions. The peak psoriasis incidence typically occurs between the ages of 20 and 60. Additionally, it has been observed that roughly one-third of cases begin in childhood.
Discover evolving trends in the Severe Psoriasis patient pool forecasts @ Severe Psoriasis Epidemiology Analysis [https://www.delveinsight.com/sample-request/severe-psoriasis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The current severe psoriasis treatment landscape is dominated by biologic therapies targeting specific inflammatory pathways. BIMZELX from UCB, an interleukin-17A and interleukin-17F antagonist approved by the FDA in October 2023, has demonstrated superior efficacy in moderate-to-severe plaque psoriasis patients. The psoriasis therapeutic landscape also includes SOTYKTU, the first oral tyrosine kinase 2 (TYK2) inhibitor manufactured by Bristol Myers Squibb, alongside established interleukin-23 antagonists such as SKYRIZI (AbbVie), ILUMYA (Sun Pharma), and TREMFYA (Janssen Biotech). These targeted therapies represent a significant advancement over conventional systemic treatments and are rapidly gaining market share in treatment-refractory patient populations.
Several promising pipeline drugs are advancing the psoriasis treatment landscape, targeting different subtypes of the disease. Notable candidates include Picankibart (IBI112), a monoclonal antibody injection targeting IL-23, manufactured by Innovent Biologics; Icotrokinra (JNJ-2113), a first-in-class oral IL-23 inhibitor, manufactured by Johnson & Johnson; and Ebdarokimab (AK 101), an IL-12/23 monoclonal antibody, manufactured by Akeso, Inc.
For generalized pustular psoriasis, Imsidolimab (ANB019), an IL-36 receptor blocker, provided rapid and lasting relief, with over half of the patients achieving clear or almost clear skin in phase III studies. Other oral agents in development include piclidenoson (CF101), an A3 adenosine receptor agonist, and TYK2 inhibitors such as ESK-001 and ICP-488, both demonstrating significant symptom improvement in early trials.
Additionally, vibozilimod (SCD-044), an S1P1 receptor-1 agonist, is in phase II trials and shows potential for effective inflammation control. These pipeline drugs represent a new generation of targeted therapies aiming for higher efficacy, improved safety, and greater patient convenience.
Recent advancements in topical formulations are addressing the unmet needs in the severe psoriasis drug market. In March 2025, BIMZELX received further FDA approvals for psoriatic arthritis. Simultaneously, Johnson & Johnson announced Phase III results for icotrokinra, a first-in-class oral peptide that selectively blocks the IL-23 receptor. Nearly half of the patients achieved completely clear skin at 24 weeks, and the drug showed superiority to the oral TYK2 inhibitor deucravacitinib. This marks a potential shift toward oral therapies rivaling injectables in efficacy.
Discover evolving trends in the Severe Psoriasis treatment landscape @ Severe Psoriasis Recent Developments [https://www.delveinsight.com/sample-request/severe-psoriasis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The major pharmaceutical companies dominating the severe psoriasis therapeutic market include Johnson & Johnson (NYSE: JNJ), Pfizer Inc. (NYSE: PFE), LEO Pharma, Novartis AG (SWX: NOVN), Biocon Biologics (NSE: BIOCON), AbbVie Inc. (NYSE: ABBV), Eli Lilly and Company (NYSE: LLY), Sun Pharmaceutical Industries Ltd. (NSE: SUNPHARMA), Merck & Co., Inc. (NYSE: MRK), Evelo Biosciences, Inc. (NASDAQ: EVLO), Bausch Health Companies Inc. (NYSE: BHC), Amgen Inc. (NASDAQ: AMGN), Bristol-Myers Squibb Company (NYSE: BMY), Galderma S.A. (SIX: GALD), and InnoCare Pharma (HKEX: 9969), among others, investing heavily in novel mechanism approaches to address treatment gaps and improve patient outcomes.
The competitive landscape [https://www.delveinsight.com/sample-request/severe-psoriasis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr] underscores substantial commercial interest in this therapeutic area, with significant research directed toward developing more effective and convenient treatment options for patients with severe forms of the disease. Furthermore, the introduction of biosimilars is intensifying competition, offering more cost-effective alternatives to originator biologics.
Looking ahead, the severe psoriasis market is poised for continued expansion driven by the introduction of novel oral targeted therapies, next-generation biologics with enhanced efficacy profiles, and combination regimens addressing multiple inflammatory pathways simultaneously. As understanding of disease pathophysiology advances, precision medicine approaches are expected to emerge, allowing for more personalized treatment strategies based on individual patient characteristics and biomarker profiles.
Table of Contents
1. Key Insights
2. Executive Summary of Severe Psoriasis
3. Competitive Intelligence Analysis for Severe Psoriasis
4. Severe Psoriasis: Market Overview at a Glance
5. Severe Psoriasis: Disease Background and Overview
6. Severe Psoriasis Patient Journey
7. Severe Psoriasis Epidemiology and Patient Population
8. Severe Psoriasis Treatment Algorithm, Current Treatment, and Medical Practices
9. Severe Psoriasis Unmet Needs
10. Key Endpoints of Severe Psoriasis Treatment
11. Severe Psoriasis Marketed Products
12. Severe Psoriasis Emerging Therapies
13. Severe Psoriasis: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Severe Psoriasis
17. KOL Views
18. Severe Psoriasis Market Drivers
19. Severe Psoriasis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=severe-psoriasis-market-expected-to-show-robust-growth-through-2032-driven-by-novel-biologics-and-oral-therapeutics-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Severe Psoriasis Market Expected to Show Robust Growth Through 2032, Driven by Novel Biologics and Oral Therapeutics | DelveInsight here
News-ID: 4013324 • Views: …
More Releases from ABNewswire

Secure Z100 Jingle Ball MSG Seats Fast with Promo Code CITY10: Dec 12, 2025 at C …
Grab your Z100 Jingle Ball tickets at Madison Square Garden for Dec 12, 2025, fast with CapitalCityTickets.com! Use promo code CITY10 to save instantly. Don't miss performances from top artists, festive vibes, and unforgettable holiday music. Secure the best seats online today and enjoy an epic night of live entertainment at one of New York City's most iconic venues.
The Z100 Jingle Ball is back, lighting up Madison Square Garden (MSG)…

Cheapest Knicks Tickets Basketball Tickets Online - Best Prices Available with P …
Get your New York Knicks tickets online at CapitalCityTickets.com and score the cheapest prices with promo code CITY10. Whether you want courtside action or upper-level seats at Madison Square Garden, fans can enjoy NBA games without overspending. Don't miss live basketball excitement featuring Julius Randle, RJ Barrett, and the Knicks - buy your tickets today for every home game this season.
The 2025-26 NBA season is here, and New York Knicks…

Fiber Optic Cable Market Expected to Reach USD 20.94 Billion by 2030, Driven by …
Mordor Intelligence has published a new report on the Fiber Optic Cable Market, offering a comprehensive analysis of trends, growth drivers, and future projections.
Fiber Optic Cable Market Overview
The Fiber Optic Cable Market size is estimated at USD 13.92 billion in 2025, and is expected to reach USD 20.94 billion by 2030, at a CAGR of 10.46% during the forecast period (2025-2030). The market reflects increasing demand for high-speed internet, 5G…

Upgraded Systems Made Possible with Water Heater Installation in Wilmington
By ensuring reliable systems are available in homes and businesses, Powell's Plumbing & Air has become a trusted resource for essential upgrades and high-quality service.
In Wilmington, NC, demand for modern solutions such as water heater installation near me [https://www.google.com/search?water+heater+installation+near+me&kgmid=/g/1tfqb2fb] continues to grow as property owners look for ways to improve comfort and efficiency. By ensuring reliable systems are available in homes and businesses, Powell's Plumbing & Air has become a…
More Releases for Severe
Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Clinical Trials, Compan …
DelveInsight's "Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne, historical and forecasted epidemiology as well as the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight's analysis highlights that several key companies are actively…
Severe Combined Immunodeficiency (SCID) Market: A Comprehensive Overview
Severe Combined Immunodeficiency (SCID) is a rare but life-threatening genetic disorder that affects the immune system, leaving individuals vulnerable to infections. It is often referred to as "bubble boy disease," due to its dramatic impact on the immune system, which fails to protect the body from pathogens. SCID can be caused by various mutations in different genes, and it leads to a complete or near-complete absence of functional T-cells and…
Severe Breathing Care Ventilator Market Size 2024 to 2031.
Market Overview and Report Coverage
The Severe Breathing Care Ventilator Market refers to the market for medical devices that help patients with severe breathing difficulties by providing assistance with their respiration. These ventilators are crucial in treating patients with conditions such as respiratory failure, chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome (ARDS).
The future outlook for the Severe Breathing Care Ventilator Market is very promising, with a…
Severe Asthma Treatment Market - Revitalizing Quality of Life: Severe Asthma Tre …
Newark, New Castle, USA: The "Severe Asthma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Severe Asthma Treatment Market: https://www.growthplusreports.com/report/severe-asthma-treatment-market/8939
This latest report researches the industry structure,…
Severe Hypertriglyceridemia Market - Breaking Barriers in Managing Cholesterol L …
Newark, New Castle, USA: The "Severe Hypertriglyceridemia Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Severe Hypertriglyceridemia Market: https://www.growthplusreports.com/report/severe-hypertriglyceridemia-market/8763
This latest report researches the industry structure, sales, revenue,…
Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2017, provides an overview of the Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline landscape.
Severe acute respiratory syndrome (SARS) is a serious, potentially…